
Vigil Neuroscience (VIGL) Stock Forecast & Price Target
Vigil Neuroscience (VIGL) Analyst Ratings
Bulls say
Vigil Neuroscience Inc. is benefiting from a potential accelerated approval pathway that hinges on demonstrating a significant reduction in neurodegeneration metrics, such as NfL and changes in ventricular or gray matter volume. The promising results from VG-3927, which showed a dose-dependent reduction in sTREM2 and boasts a favorable safety profile, position the company well for finding a commercial partner to further develop this asset. Additionally, with a current negative enterprise value of $25 million, there appears to be considerable upside potential for Vigil Neuroscience's stock, especially if forthcoming clinical data support the efficacy of its therapeutics.
Bears say
Vigil Neuroscience Inc has experienced significant pressure on its stock, with a decline of 26% following the ALEC TREM2 data readout, indicating investor concerns about the company's performance and future prospects. The company reported a substantial net loss of $23.8 million in its fourth quarter, resulting in a GAAP EPS of $(0.57), which was worse than analyst expectations, further highlighting potential operational challenges. Additionally, the increase in the discount rate to 35% has necessitated a downward revision of the valuation target, now set at $13, which underscores a fundamental negative outlook based on current financial metrics and the risk of commercial execution failure.
This aggregate rating is based on analysts' research of Vigil Neuroscience and is not a guaranteed prediction by Public.com or investment advice.
Vigil Neuroscience (VIGL) Analyst Forecast & Price Prediction
Start investing in Vigil Neuroscience (VIGL)
Order type
Buy in
Order amount
Est. shares
0 shares